<DOC>
	<DOCNO>NCT00080405</DOCNO>
	<brief_summary>The purpose study characterize clinical pharmacokinetic pharmacodynamic profile 2 dos VELCADE ( bortezomib ) Injection . Patients volunteer participate pharmacogenetic portion study , additional blood sample collect Cycle 1 Day 1 dose bortezomib assess genotype drug metabolize enzyme .</brief_summary>
	<brief_title>Repeat-Dose Pharmacokinetics Pharmacodynamics Bortezomib Patients With Relapsed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Male female adult patient 18 year old diagnosis relapse multiple myeloma require therapy eligible study . Key inclusion criterion include : Karnofsky Performance Status ( KPS ) equal great 70 % , normal liver function test ( aspartate transaminase [ AST ] alanine transaminase [ ALT ] equal less 2 x upper limit normal [ ULN ] , total bilirubin equal le 1.5 x ULN ) , hemoglobin equal great 10 g/dL , platelet equal great 50 x 10 ninth power/L , absolute neutrophil count ( ANC ) equal great 1000/uL ; calculate creatinine clearance equal great 50 mL/min , normal serum calcium . Key exclusion criterion include : Patients significant cardiac disease , equal great Grade 2 neuropathy , active hepatitis , HIV infection , secondary malignancy , POEMS syndrome , plasma cell leukemia , transfusiondependent receive extensive radiation therapy , systemic chemotherapy , antineoplastic therapy within 4 week enrollment exclude . Patients take concurrent medication entry may act inducer inhibitor CYP 3A4 exclude . Patients receive thalidomide must discontinue drug least 2 week prior enrollment . Patients receive concurrent corticosteroid must taper dose corticosteroid equal less 10 mg/day prednisone prednisone equivalent least 2 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
</DOC>